Chemical Biology of Nuclear Receptor Action in the Macrophage

巨噬细胞核受体作用的化学生物学

基本信息

  • 批准号:
    7868719
  • 负责人:
  • 金额:
    $ 48.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-01 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Obesity is a major health problem in the United States. It increases the risk of insulin resistance (IR) and metabolic syndrome (MS), a cluster of cardiovascular disease (CVD) risk factors, and leads to additional pathologies, including non-alcoholic steatohepatitis (NASH), the second most common cause of liver cirrhosis; Alzheimer's disease; cardiomyopathy; cancer; and others, many associated with or exacerbated by aging. In principle, it should be simple to treat and prevent obesity with lifestyle modifications (diet and exercise) but these approaches have not worked well. It is therefore essential to develop innovative treatments for obesity and IR. Over the last ten years, it has become clear that obesity/IR is related to low- grade systemic inflammation and that the polarization state of adipose tissue macrophages (ATMs) is the important link between these seemingly disparate phenomena. Ml pro-inflammatory macrophages secrete factors that inhibit local and systemic insulin signaling whereas alternatively activated M2 macrophages counter the pro-inflammatory actions of Ml macrophages and enhance insulin sensitivity and blunt harmful effects of high fat diet. Recent data indicates that three nuclear receptors (NRs) are important for elaboration of M2 macrophage phenotype, peroxisome proliferator activated receptors (PPARs) y and 6 and estrogen receptor a (ERa). In addition, at least 20 other NRs are expressed in macrophages and effects of activation of these NRs in macrophage are unknown. In this proposal, we will assemble a team to understand the best way to selectively manipulate NR signaling in ATMs to inhibit metabolic disease while avoiding typical harmful side effects of NR ligands on the body. Our team brings together scientists from different institutions who are experts in NR actions in animal models of metabolic disease and macrophages, NR structure and molecular biology, chemical biology of NR action and NR genomics and natural NR ligands. We believe that this team will be well equipped to define ways to target macrophage NRs and develop new ligands to selectively manipulate NR signaling in this cell type and that the R24 mechanism will be perfect to help us form a team with a strong focus on chemical biology of NR action in macrophage. RELEVANCE: The nuclear receptors are an important protein family that is a well established target for drug development. 20% of current US prescriptions are for nuclear receptor ligands. Drugs that modulate activities of NRs in the macrophage could combat inflammation that contributes to insulin resistance, obesity and other aspects of metabolic syndrome, one of the biggest health problems facing the United States today.
描述(由申请人提供):肥胖是美国的主要健康问题。它增加了胰岛素抵抗(IR)和代谢综合征(MS)的风险,这是一组心血管疾病(CVD)风险因素,并导致其他病理学,包括非酒精性脂肪性肝炎(NASH),肝硬化的第二大常见原因;阿尔茨海默病;心肌病;癌症;以及其他许多与衰老相关或因衰老而加剧的疾病。原则上,通过改变生活方式(饮食和运动)来治疗和预防肥胖应该很简单,但这些方法效果不佳。因此,开发肥胖和IR的创新治疗方法是至关重要的。在过去的十年中,已经清楚的是,肥胖/IR与低度全身性炎症有关,并且脂肪组织巨噬细胞(ATM)的极化状态是这些看似不同的现象之间的重要联系。Ml促炎巨噬细胞分泌抑制局部和全身胰岛素信号传导的因子,而交替活化的M2巨噬细胞对抗Ml巨噬细胞的促炎作用并增强胰岛素敏感性和减弱高脂肪饮食的有害作用。最近的数据表明,三种核受体(NR)对于M2巨噬细胞表型的形成是重要的,过氧化物酶体增殖物激活受体(PPARs)γ和6以及雌激素受体α(ER α)。此外,至少20种其他NR在巨噬细胞中表达,并且这些NR在巨噬细胞中的活化作用是未知的。在这项提案中,我们将组建一个团队,以了解选择性操纵ATM中NR信号传导的最佳方式,以抑制代谢疾病,同时避免NR配体对身体的典型有害副作用。我们的团队汇集了来自不同机构的科学家,他们是代谢疾病和巨噬细胞动物模型中NR作用的专家,NR结构和分子生物学,NR作用的化学生物学和NR基因组学以及天然NR配体。我们相信,这个团队将有能力定义靶向巨噬细胞NR的方法,并开发新的配体来选择性地操纵这种细胞类型中的NR信号传导,R24机制将是完美的,可以帮助我们组建一个专注于巨噬细胞中NR作用的化学生物学的团队。 相关性:核受体是一个重要的蛋白质家族,是药物开发的既定目标。目前美国20%的处方是核受体配体。调节巨噬细胞中NR活性的药物可以对抗导致胰岛素抵抗、肥胖和代谢综合征其他方面的炎症,这是美国当今面临的最大健康问题之一。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Willa A Hsueh其他文献

Pharmacologic treatment options for prediabetes
针对糖尿病前期的药物治疗选择
  • DOI:
    10.1038/ncpendmet0842
  • 发表时间:
    2008-06-03
  • 期刊:
  • 影响因子:
    40.000
  • 作者:
    Willa A Hsueh;Yehuda Handelsman
  • 通讯作者:
    Yehuda Handelsman
816-4 Effect of glucose lowering on coronary circulatory dysfunction in type 2 diabetes mellitus
  • DOI:
    10.1016/s0735-1097(04)91437-4
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    Alvaro D Facta;John O Prior;Thomas H Schindler;Jerson Cadenas;Manuel J Quinones;Willa A Hsueh;Heinrich R Schelbert
  • 通讯作者:
    Heinrich R Schelbert

Willa A Hsueh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Willa A Hsueh', 18)}}的其他基金

Postdoctoral Training in Cardiometabolic Science
心脏代谢科学博士后培训
  • 批准号:
    10684162
  • 财政年份:
    2020
  • 资助金额:
    $ 48.86万
  • 项目类别:
Postdoctoral Training in Cardiometabolic Science
心脏代谢科学博士后培训
  • 批准号:
    10473596
  • 财政年份:
    2020
  • 资助金额:
    $ 48.86万
  • 项目类别:
Postdoctoral Training in Cardiometabolic Science
心脏代谢科学博士后培训
  • 批准号:
    10242188
  • 财政年份:
    2020
  • 资助金额:
    $ 48.86万
  • 项目类别:
Postdoctoral Training in Cardiometabolic Science
心脏代谢科学博士后培训
  • 批准号:
    10024795
  • 财政年份:
    2020
  • 资助金额:
    $ 48.86万
  • 项目类别:
Impact of the Adipose Tissue Microenvironment on Atherosclerosis
脂肪组织微环境对动脉粥样硬化的影响
  • 批准号:
    10063545
  • 财政年份:
    2017
  • 资助金额:
    $ 48.86万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    7425746
  • 财政年份:
    2008
  • 资助金额:
    $ 48.86万
  • 项目类别:
Transcriptional Genomics Core
转录基因组学核心
  • 批准号:
    7500497
  • 财政年份:
    2007
  • 资助金额:
    $ 48.86万
  • 项目类别:
Human Genetics Core
人类遗传学核心
  • 批准号:
    7500502
  • 财政年份:
    2007
  • 资助金额:
    $ 48.86万
  • 项目类别:
Mouse Phenotyping Core
小鼠表型核心
  • 批准号:
    7500488
  • 财政年份:
    2007
  • 资助金额:
    $ 48.86万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7500510
  • 财政年份:
    2007
  • 资助金额:
    $ 48.86万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 48.86万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 48.86万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了